COMMAND CENTER REVIEW INTERFACE
Review Prioritization
Organizes pattern-based review notifications into a ranked queue to support efficient clinical workflow review.
Displays already-acquired numeric vital-sign observations for authorized health care professional review. Presents relevant trend context to help authorized health care professionals independently review the basis for each notification.
Internal Retrospective Aggregate Evaluation
Early Risk Alert AI has conducted internal retrospective aggregate testing using publicly available critical-care datasets, including MIMIC-IV and eICU. These internal analyses evaluated review-notification volume relative to standard single-parameter threshold alerting and included retrospective lead-time context relative to documented clinical events. Performance characteristics vary by dataset, event definition, and operating threshold. These findings are provided for informational purposes only. They do not constitute prospective clinical validation, diagnostic-performance claims, or proof of patient-outcome improvement. HiRID status: Access approved; local/private retrospective aggregate evaluation pending.
Retrospective Review Context
Evaluates review-notification behavior relative to standard single-parameter threshold alerting.
MIMIC-IV and eICU Analysis
Retrospective aggregate analysis of review-notification frequency and documented clinical-event context.
Dataset Variability
Findings depend on dataset, event definition, and operating threshold.
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
RETROSPECTIVE EVIDENCE SUMMARY
This section summarizes retrospective, de-identified, aggregate findings from defined historical evidence tracks. Metrics must be interpreted within their respective dataset, event-definition, and operating-threshold boundaries. These findings do not constitute prospective clinical validation, diagnostic-performance claims, or proof of patient-outcome improvement.
MIMIC-IV STRICT CLINICAL-EVENT TRACK
Retrospective Aggregate Evaluation
Maintains dataset-specific retrospective evidence with defined clinical-event and operating-threshold boundaries.
eICU RETROSPECTIVE EVIDENCE TRACKS
Interpret Separately
Outcome-proxy and harmonized clinical-event tracks are maintained as distinct retrospective evidence tracks.
HiRID STATUS
Access Approved
Local/private retrospective aggregate evaluation pending.
EVIDENCE-TRACK BOUNDARY
Do Not Merge Metrics
Performance characteristics vary by dataset, event definition, and operating threshold. Detailed metrics are maintained in controlled private evidence materials.
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
Trial Scope
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
SUPPORT REVIEW
Supports authorized healthcare professionals in reviewing already-acquired numeric vital-sign observations within controlled pilot-stage workflows.
ORGANIZE REVIEW ITEMS
Organizes pattern-based review notifications into a structured queue for independent professional review.
CONTROLLED ACCESS
Uses credentialed access and activity logging to support accountable pilot-stage platform use.
RETROSPECTIVE EVIDENCE
Supports review of retrospective, de-identified, aggregate findings with dataset-specific evidence boundaries.
Healthcare Workflow Oversight
Early Risk Alert AI supports explainable review prioritization, monitored-workflow visibility, and controlled pilot-stage evaluation.
HOSPITAL TEAMS
Supports authorized healthcare professionals with review-queue visibility and explainable context during controlled pilot-stage evaluation.
CLINICAL WORKFLOW PARTNERS
Supports structured review-prioritization workflows, accountable platform use, and evaluation planning with authorized stakeholders.
STRATEGIC STAKEHOLDERS
Supports discussion of retrospective aggregate findings, workflow fit, governance readiness, and future pilot planning.
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
Security and Governance
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
CREDENTIALED ACCESS
Role-based controls restrict access to authorized users.
ACTIVITY LOGGING
Activity logging supports auditability and accountable platform use.
PROTECTED DATA HANDLING
Encryption and access-control capabilities support protected-data handling in controlled pilot-stage environments.
CONTROLLED PILOT USE
Current pilot portals are limited to de-identified evaluation data. No live PHI flows are active.
REQUEST A SYSTEM TOUR
Decision-support-only platform overview for controlled pilot-stage discussions.
PLATFORM OVERSIGHT
Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
PILOT-STAGE SUPPORT
Explainable Review Prioritization for Authorized Clinical Teams
Early Risk Alert AI is a pilot-stage, pre-commercial healthcare-professional-facing decision-support and workflow-support software platform designed for adult hospital ICU and acute-care settings. The platform organizes already-acquired numeric vital-sign observations and presents pattern-based review notifications to authorized health care professionals for their independent review.
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, independently trigger escalation, or replace bedside monitoring systems, immediate physiologic alarms, or hospital emergency-response systems.
EVALUATIVE PARTNERSHIP PATH
Workflow Evaluation Path
Current development work focuses on controlled pilot-stage evaluation, governance readiness, and review-workflow refinement using retrospective, de-identified, aggregate evidence.
CLINICAL WORKFLOW REVIEW
Supports structured discussion of review-queue design, explainability, and monitored-workflow fit with authorized clinical stakeholders.
STRATEGIC DEVELOPMENT
Supports discussion of governance readiness, technical milestones, and controlled pilot-stage planning.
RETROSPECTIVE EVIDENCE
Summarizes retrospective, de-identified, aggregate findings with dataset-specific evidence boundaries.
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
Supporting Pilot-Stage Review-Prioritization Workflows
EXPLAINABLE REVIEW CONTEXT
Presents contributing numeric variables and available trend context to support independent professional review.
WORKFLOW VISIBILITY
Supports monitored-workflow awareness and review-queue visibility during controlled pilot-stage evaluation.
ACTIVITY AND ENGAGEMENT LOGS
Tracks platform activity to support auditability, accountability, and controlled evaluation review.
RETROSPECTIVE AGGREGATE ENGINE
Supports analysis of retrospective, de-identified, aggregate evidence within defined dataset and operating-threshold boundaries.
CREDENTIALED USER ACCESS
Restricts platform access to authorized users within controlled pilot-stage environments.
DECISION-SUPPORT BOUNDARY
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
RETROSPECTIVE EVIDENCE SUMMARY
Workflow Evaluation Data Summary
This section summarizes retrospective, de-identified, aggregate evidence tracks related to review-prioritization workflows. Detailed operating-point metrics are maintained in controlled private evidence materials. Findings must be interpreted within their respective dataset, event-definition, and operating-threshold boundaries.
MIMIC-IV STRICT CLINICAL-EVENT TRACK
Retrospective Aggregate Evaluation
Maintains dataset-specific evidence related to review-notification behavior and documented clinical-event context.
MIMIC-IV CROSS-COHORT REVIEW
Defined Evidence Track
Supports controlled retrospective review across defined historical cohorts with explicit methodology boundaries.
eICU OUTCOME-PROXY TRACK
Retrospective Aggregate Evaluation
Maintains a separate retrospective outcome-proxy evidence track for controlled internal review.
eICU HARMONIZED CLINICAL-EVENT TRACK
Interpret Separately
Maintains a distinct harmonized clinical-event evidence track. Metrics must not be merged across evidence tracks.
Detailed operating-point metrics are maintained in controlled private evidence materials. Performance characteristics vary by dataset, event definition, and operating threshold.
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
Evidence and Retrospective Data
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
MIMIC-IV STRICT CLINICAL-EVENT TRACK
Retrospective Aggregate Evaluation
Maintains dataset-specific retrospective evidence with defined clinical-event and operating-threshold boundaries.
HiRID STATUS
Access Approved
Local/private retrospective aggregate evaluation pending.
eICU RETROSPECTIVE EVIDENCE TRACKS
Interpret Separately
Outcome-proxy and harmonized clinical-event tracks are maintained as distinct retrospective evidence tracks.
EVIDENCE-TRACK BOUNDARY
Do Not Merge Metrics
Performance characteristics vary by dataset, event definition, and operating threshold. Detailed metrics are maintained in controlled private evidence materials.
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
Governance Registry & Stakeholder Readiness
Decision support only. Early Risk Alert AI does not diagnose, direct treatment, replace clinician judgment, or independently trigger escalation.
RETROSPECTIVE EVIDENCE RECORDS
Maintains documented retrospective, de-identified, aggregate evidence materials with dataset-specific methodology boundaries.
REGULATORY INFORMATION PATH
Section 513(g) request materials are being prepared to seek FDA information regarding classification and applicable regulatory requirements.
CONTROLLED EVALUATION PATH
Supports structured pilot-stage planning, clinician review, usability evaluation, and governance-readiness discussions.
PHASED DEVELOPMENT
Current work focuses on documentation, retrospective aggregate evaluation, workflow refinement, and preparation for future controlled studies.